Overview

A Phase I Study of SHR1459 in Healthy Subjects

Status:
Completed

Trial end date:
2020-08-14

Target enrollment:

Participant gender:

Summary

Following a 10-hour overnight fast, subjects will be administered one dose of SHR1459 orally with 240 mL of ambient temperature water on Day 1. D2-D3 was the cleaning period. Itraconazole will be administered orally 200 mg/time/day form D4 to D8 after meal. On D7 following a 10-hour overnight fast, subjects will be administered SHR1459 and itraconazole 200 mg with 240 mL of ambient temperature water.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Collaborator:

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Treatments:

Itraconazole